Halozyme Therapeutics received European regulatory approval, while Morgan Stanley upgraded its stock and it filed a patent lawsuit against Merck Sharp & Dohme.
3 reports, 3 independent
Updated Aug 29
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Halozyme Therapeutics received European regulatory approval, while Morgan Stanley upgraded its stock and it filed a patent lawsuit against Merck Sharp & Dohme.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Merck Sharp & Dohme
company in Madrid, Spain
Nothing else this week.
-
Morgan Stanley
U.S. investment bank
-
Halozyme Therapeutics
Nothing else this week.
Coverage
Newest first; wire copies grouped- Insider MonkeyHalozyme Therapeutics, Inc. (HALO) Hikes 2025 Guidance on ENHANZE Demand We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Halozyme Therapeutics, Inc. is one
- PR NewswireHALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS Total Revenue Increased 41% YOY to $326 million and Royalty Revenue Increased 65% YOY to $206 million Net
- GuruFocus.comHalozyme Therapeutics Inc (HALO) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... Total Revenue: $326 million, a 41% increase over the prior year's second quarter. Royalty Revenue: $20